Drug intelligence / Profile preview

Alsareen

Development stage: Preclinical
Lead developer: Hamdard Pakistan
Administration: Oral

Overview

**Alsareen** is a DRAP-registered Unani herbal capsule manufactured by Hamdard Pakistan. It is a fixed traditional botanical preparation containing *Carum carvi*, *Curcuma caesia*, and *Pistacia lentiscus*, evaluated for management of *Helicobacter pylori* infection. A completed registered study, NCT06304532, evaluated oral Alsareen at 450 mg twice daily for six weeks followed by a two-week washout; the registry record does not establish a defined molecular target or confirm clinical efficacy. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06304532?tab=study))

Brand names: Alsareen

Beyond the preview

Go deeper on Alsareen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alsareen.

Explore the full profile